

Alex Prat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8319241/publications.pdf>

Version: 2024-02-01

319
papers

33,413
citations

9756

73
h-index

4323

173
g-index

334
all docs

334
docs citations

334
times ranked

38079
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive molecular portraits of human breast tumours. <i>Nature</i> , 2012, 490, 61-70.	13.7	10,282
2	Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R68.	2.2	1,748
3	Deconstructing the molecular portraits of breast cancer. <i>Molecular Oncology</i> , 2011, 5, 5-23.	2.1	1,059
4	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	0.6	891
5	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	13.9	854
6	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
7	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015, 24, S26-S35.	0.9	735
8	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. <i>Cell Reports</i> , 2013, 4, 1116-1130.	2.9	539
9	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. <i>Cancer Discovery</i> , 2012, 2, 1036-1047.	7.7	507
10	Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031. <i>Journal of Clinical Oncology</i> , 2011, 29, 2342-2349.	0.8	470
11	Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 203-209.	0.8	464
12	Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. <i>Oncologist</i> , 2013, 18, 123-133.	1.9	454
13	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. <i>Cancer Research</i> , 2013, 73, 4885-4897.	0.4	394
14	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
15	USP15 stabilizes TGF- β 2 receptor I and promotes oncogenesis through the activation of TGF- β 2 signaling in glioblastoma. <i>Nature Medicine</i> , 2012, 18, 429-435.	15.2	342
16	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	2.3	331
17	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017, 77, 3540-3550.	0.4	327
18	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3761-3766.	3.3	291

#	ARTICLE	IF	CITATIONS
19	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. <i>Annals of Oncology</i> , 2014, 25, 552-563.	0.6	290
20	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-“positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	5.8	276
21	GeneFu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. <i>Bioinformatics</i> , 2016, 32, 1097-1099.	1.8	255
22	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. <i>BMC Medical Genomics</i> , 2012, 5, 44.	0.7	250
23	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 545-554.	5.1	250
24	Practical implications of gene-expression-based assays for breast oncologists. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 48-57.	12.5	242
25	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWf1 and IL-11. <i>Nature Communications</i> , 2013, 4, 1393.	5.8	209
26	How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju165-dju165.	3.0	191
27	Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. <i>Clinical Cancer Research</i> , 2014, 20, 511-521.	3.2	191
28	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 523-535.	1.1	189
29	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. <i>Journal of Clinical Investigation</i> , 2012, 122, 1541-1552.	3.9	187
30	Defining the cellular precursors to human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2772-2777.	3.3	185
31	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	178
32	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	2.2	175
33	Mammary development meets cancer genomics. <i>Nature Medicine</i> , 2009, 15, 842-844.	15.2	171
34	Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 237-255.	1.1	169
35	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
36	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2213-2221.	0.4	168

#	ARTICLE	IF	CITATIONS
37	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 771-781.	5.2	167
38	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. <i>Lancet Oncology</i> , 2021, 22, 489-498.	5.1	157
39	PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 301-306.	1.1	156
40	The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 531-542.	4.3	153
41	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151
42	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
43	Tankyrase Inhibition Blocks Wnt/ β -Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 644-656.	3.2	143
44	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. <i>BMC Medical Genomics</i> , 2011, 4, 3.	0.7	142
45	The Hippo Transducer TAZ Interacts with the SWI/SNF Complex to Regulate Breast Epithelial Lineage Commitment. <i>Cell Reports</i> , 2014, 6, 1059-1072.	2.9	139
46	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , 2019, 20, 1360-1369.	5.1	131
47	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. <i>Annals of Oncology</i> , 2012, 23, 2866-2873.	0.6	123
48	Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. <i>Oncologist</i> , 2014, 19, 1076-1083.	1.9	122
49	miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. <i>Clinical Cancer Research</i> , 2017, 23, 1091-1103.	3.2	114
50	Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-like Breast Cancer. <i>Cancer Cell</i> , 2012, 21, 626-641.	7.7	113
51	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , 2015, 13, 303.	2.3	113
52	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. <i>Annals of Oncology</i> , 2016, 27, 1867-1873.	0.6	109
53	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	3.2	108
54	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2551-2563.	3.9	108

#	ARTICLE	IF	CITATIONS
55	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 33-43.	5.1	105
56	MAP3K4/CBP-Regulated H2B Acetylation Controls Epithelial-Mesenchymal Transition in Trophoblast Stem Cells. <i>Cell Stem Cell</i> , 2011, 8, 525-537.	5.2	102
57	Current and Future Management of HER2-Positive Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 594-604.	1.4	102
58	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 1532-1541.	2.9	100
59	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. <i>Nature Cell Biology</i> , 2018, 20, 211-221.	4.6	98
60	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	3.0	97
61	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 457-466.	1.1	96
62	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , 2016, 2, 1287.	3.4	96
63	Clinical implementation of the intrinsic subtypes of breast cancer. <i>Lancet Oncology</i> , The, 2010, 11, 718-719.	5.1	92
64	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	3.4	92
65	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 373-382.	1.1	90
66	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv256.	3.0	90
67	Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. <i>Head and Neck</i> , 2008, 30, 680-683.	0.9	87
68	Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. <i>Breast Cancer Research</i> , 2011, 13, R125.	2.2	87
69	Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor Initiation. <i>Stem Cell Reports</i> , 2014, 2, 633-647.	2.3	85
70	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CeTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. <i>Annals of Oncology</i> , 2018, 29, 170-177.	0.6	84
71	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	3.2	82
72	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. <i>Clinical Cancer Research</i> , 2013, 19, 6787-6801.	3.2	80

#	ARTICLE	IF	CITATIONS
73	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
74	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clinical Cancer Research, 2016, 22, 560-566.	3.2	79
75	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treatment Reviews, 2018, 67, 63-70.	3.4	79
76	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. Journal of Clinical Investigation, 2018, 128, 3887-3905.	3.9	79
77	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apolisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research, 2019, 25, 2975-2987.	3.2	76
78	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Annals of Oncology, 2018, 29, 2121-2128.	0.6	74
79	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. Journal of Clinical Oncology, 2021, 39, 1458-1467.	0.8	73
80	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	5.1	73
81	SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene, 2015, 34, 671-680.	2.6	72
82	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clinical Cancer Research, 2020, 26, 5820-5829.	3.2	68
83	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nature Communications, 2020, 11, 385.	5.8	67
84	The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 221-226.	3.3	64
85	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Annals of Oncology, 2019, 30, 921-926.	0.6	64
86	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 709-713.	0.9	63
87	Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. British Journal of Cancer, 2012, 107, 1249-1256.	2.9	62
88	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. Clinical Chemistry, 2017, 63, 751-760.	1.5	62
89	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. Stem Cell Reports, 2017, 8, 1392-1407.	2.3	62
90	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1301-E1310.	3.3	61

#	ARTICLE	IF	CITATIONS
91	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	2.2	60
92	Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 858-871.	5.1	60
93	Update on novel therapeutic agents for cervical cancer. <i>Gynecologic Oncology</i> , 2008, 110, S72-S76.	0.6	59
94	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	1.1	59
95	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	3.0	59
96	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1777-1786.	2.9	58
97	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020, 12, 1841.	1.7	58
98	Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice. <i>Clinical Cancer Research</i> , 2013, 19, 4889-4899.	3.2	56
99	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. <i>Cell Reports</i> , 2017, 21, 2183-2197.	2.9	56
100	Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. <i>Annals of Oncology</i> , 2008, 19, 327-331.	0.6	54
101	SWI/SNF Chromatin-Remodeling Factor Smarcd3/Baf60c Controls Epithelial-Mesenchymal Transition by Inducing Wnt5a Signaling. <i>Molecular and Cellular Biology</i> , 2013, 33, 3011-3025.	1.1	54
102	A Rare Case of Malignant Solitary Fibrous Tumor of the Spinal Cord. <i>Spine</i> , 2008, 33, E397-E399.	1.0	52
103	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	5.1	52
104	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. <i>Journal of Clinical Oncology</i> , 2020, 38, 1006-1006.	0.8	52
105	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler. <i>Cancers</i> , 2021, 13, 4456.	1.7	50
106	New approaches in angiogenic targeting for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 5857.	1.4	50
107	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
108	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50

#	ARTICLE	IF	CITATIONS
109	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer, 2014, 14, 302.	1.1	49
110	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. Journal of Clinical Investigation, 2020, 130, 4871-4887.	3.9	49
111	ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. Journal of Clinical Investigation, 2013, 123, 4329-4343.	3.9	49
112	SEOM clinical guidelines in early stage breast cancer (2018). Clinical and Translational Oncology, 2019, 21, 18-30.	1.2	48
113	DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.. Journal of Clinical Oncology, 2020, 38, 5012-5012.	0.8	48
114	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine, 2022, 75, 103801.	2.7	47
115	Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clinical and Experimental Metastasis, 2014, 31, 33-45.	1.7	46
116	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast, 2017, 34, S19-S26.	0.9	46
117	Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Scientific Reports, 2013, 3, 3544.	1.6	45
118	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. European Journal of Cancer, 2021, 149, 134-152.	1.3	41
119	Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast, 2021, 59, 339-350.	0.9	41
120	Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. Molecular Oncology, 2015, 9, 1081-1090.	2.1	39
121	Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Medical Genomics, 2011, 4, 77.	0.7	38
122	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Research and Treatment, 2016, 156, 81-89.	1.1	38
123	Differentiation and Loss of Malignant Character of Spontaneous Pulmonary Metastases in Patient-Derived Breast Cancer Models. Cancer Research, 2014, 74, 7406-7417.	0.4	37
124	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. Molecular Oncology, 2014, 8, 20-26.	2.1	37
125	Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Research and Treatment, 2014, 147, 185-191.	1.1	37
126	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. Current Medical Research and Opinion, 2015, 31, 1129-1137.	0.9	37

#	ARTICLE	IF	CITATIONS
127	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. <i>Annals of Oncology</i> , 2019, 30, 927-933.	0.6	37
128	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	1.3	37
129	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	36
130	Vasculitic neuropathy induced by pembrolizumab. <i>Annals of Oncology</i> , 2017, 28, 433-434.	0.6	36
131	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	1.1	34
132	Intrinsic molecular subtypes of HER2+ breast cancer. <i>Oncotarget</i> , 2017, 8, 73362-73363.	0.8	34
133	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. <i>Oncotarget</i> , 2015, 6, 28173-28182.	0.8	34
134	Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. <i>Annals of Oncology</i> , 2009, 20, 294-297.	0.6	32
135	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 738-745.	3.2	31
136	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 4688-4698.	3.2	30
137	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
138	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1902.	1.7	29
139	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	3.2	28
140	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. <i>BMC Medicine</i> , 2019, 17, 8.	2.3	28
141	Predictive model of complexity in early palliative care: a cohort of advanced cancer patients (PALCOM) TJ ETQq1 1 0.784314 rgBT / Overl	1.0	27
142	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT trial. <i>International Journal of Cancer</i> , 2020, 146, 262-271.	2.3	27
143	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. <i>Clinical Cancer Research</i> , 2020, 26, 2783-2788.	3.2	27
144	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. <i>Npj Precision Oncology</i> , 2021, 5, 23.	2.3	26

#	ARTICLE	IF	CITATIONS
145	Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Hormonal Therapy for the Treatment of Primary HER2-Positive Breast Cancer: One More Step Toward Chemotherapy-Free Therapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 1703-1706.	0.8	25
146	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. <i>Oncologist</i> , 2019, 24, 893-900.	1.9	25
147	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 887-900.	2.1	24
148	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2022, 16, 69-87.	2.1	24
149	Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. <i>ESMO Open</i> , 2021, 6, 100102.	2.0	24
150	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 119-124.	1.2	23
151	Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2594-E2603.	3.3	23
152	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials. <i>Acta Oncologica</i> , 2018, 57, 38-43.	0.8	22
153	Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase III trial. <i>European Journal of Cancer</i> , 2021, 148, 382-394.	1.3	22
154	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 503-503.	0.8	22
155	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. <i>Breast Cancer Research</i> , 2019, 21, 108.	2.2	21
156	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 3720-3731.	3.2	21
157	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	21
158	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. <i>Molecular Cancer Research</i> , 2019, 17, 2063-2076.	1.5	20
159	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141.	1.3	20
160	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. <i>Clinical and Translational Oncology</i> , 2014, 16, 386-394.	1.2	19
161	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	1.3	19
162	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. <i>European Journal of Cancer</i> , 2019, 120, 54-64.	1.3	18

#	ARTICLE	IF	CITATIONS
163	Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. <i>Cancer Research</i> , 2019, 79, 4258-4270.	0.4	17
164	PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851.	3.2	17
165	Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 350-363.	2.1	17
166	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	1.7	17
167	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 21930-21937.	0.8	17
168	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. <i>Lung Cancer</i> , 2009, 66, 257-261.	0.9	16
169	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188487.	3.3	16
170	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 638482.	1.3	16
171	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	1.8	15
172	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	2.2	15
173	Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 9069-9069.	0.8	15
174	Acute Lung Injury Associated with Docetaxel and Bevacizumab. <i>Clinical Oncology</i> , 2007, 19, 803-805.	0.6	14
175	PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. <i>Frontiers in Oncology</i> , 2019, 9, 707.	1.3	14
176	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	14
177	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021, 7, 8.	2.3	14
178	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCC. <i>Journal of Clinical Oncology</i> , 2012, 30, 1008-1008.	0.8	14
179	Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 1008-1014.		13
180	PELO negatively regulates HER receptor signalling and metastasis. <i>Oncogene</i> , 2014, 33, 1190-1197.	2.6	13

#	ARTICLE	IF	CITATIONS
181	The influence of treatment sequence in the prognostic value of <i>TPRSS2</i> as biomarker of taxane resistance in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2019, 145, 1970-1981.	2.3	13
182	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 467-470.	3.0	13
183	Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC). <i>Cancer Research</i> , 2018, 78, PD3-06-PD3-06.	0.4	13
184	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. <i>Oncogene</i> , 2020, 39, 5455-5467.	2.6	12
185	High <i>FGFR1</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 137-149.	3.2	12
186	Chemotherapy benefit for ER-positive breast cancer and contamination of Nonluminal subtypes waiting for TAILORx and RxPONDER. <i>Annals of Oncology</i> , 2015, 26, 70-74.	0.6	11
187	Standardized versus research-based PAM50 intrinsic subtyping of breast cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 953-955.	1.2	11
188	Development and validation for research assessment of Oncotype DX [®] Breast Recurrence Score, EndoPredict [®] and Prosigna [®] . <i>Npj Breast Cancer</i> , 2021, 7, 15.	2.3	11
189	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 42.	2.2	11
190	Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL). <i>Journal of Clinical Oncology</i> , 2017, 35, 5508-5508.	0.8	11
191	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 39-49.	1.1	11
192	Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. <i>Cancer Treatment Reviews</i> , 2022, 106, 102392.	3.4	11
193	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
194	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. <i>European Journal of Radiology</i> , 2019, 117, 132-139.	1.2	10
195	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. <i>Frontiers in Oncology</i> , 2019, 9, 1178.	1.3	10
196	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021, 148, 134-145.	1.3	10
197	Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 529-529.	0.8	10
198	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 509-509.	0.8	10

#	ARTICLE	IF	CITATIONS
199	Home management of acute medical complications in cancer patients: a prospective pilot study. Supportive Care in Cancer, 2016, 24, 2129-2137.	1.0	9
200	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. Clinical Cancer Research, 2021, 27, 3116-3125.	3.2	9
201	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. Npj Breast Cancer, 2021, 7, 12.	2.3	9
202	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Npj Breast Cancer, 2021, 7, 145.	2.3	9
203	Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. Journal of Clinical Oncology, 2022, 40, 1028-1028.	0.8	9
204	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303.	1.3	8
205	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncology, 2020, 16, 1801-1813.	1.1	8
206	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. Journal of Clinical Oncology, 2019, 37, 574-574.	0.8	8
207	Abstract GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer. Cancer Research, 2022, 82, GS2-00-GS2-00.	0.4	8
208	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. ESMO Open, 2016, 1, e000032.	2.0	7
209	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. EBioMedicine, 2021, 69, 103451.	2.7	7
210	Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes. Cancers, 2021, 13, 4960.	1.7	7
211	Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study. Current Medical Research and Opinion, 2016, 32, 835-839.	0.9	6
212	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. Clinical Cancer Research, 2020, 26, 6141-6148.	3.2	6
213	The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. Cancer Research, 2021, 81, 1540-1551.	0.4	6
214	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. Journal of Clinical Oncology, 2018, 36, 507-507.	0.8	6
215	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. Journal of Clinical Oncology, 2019, 37, 544-544.	0.8	6
216	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. Journal of Clinical Oncology, 2019, 37, 571-571.	0.8	6

#	ARTICLE	IF	CITATIONS
217	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 313.	3.5	6
218	De novo metastatic breast cancer arising in young women: review of the current evidence. <i>Clinical Breast Cancer</i> , 2021, . .	1.1	6
219	14-gene immunoglobulin (IGC) and proliferation signatures and association with overall survival across cancer-types.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2636-2636.	0.8	6
220	De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4995-5003.	3.2	6
221	Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. <i>Annals of Oncology</i> , 2018, 29, viii61.	0.6	5
222	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. <i>European Journal of Cancer</i> , 2018, 92, S117-S118.	1.3	5
223	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. <i>Translational Research</i> , 2019, 208, 73-84.	2.2	5
224	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 710596.	1.3	5
225	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1101-TPS1101.	0.8	5
226	DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4588-TPS4588.	0.8	5
227	Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3015-3015.	0.8	5
228	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. <i>Cancers</i> , 2020, 12, 1124.	1.7	5
229	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	1.4	5
230	Hepatic Pneumatosis As a Complication of an Abdominal Desmoid Tumor. <i>Journal of Clinical Oncology</i> , 2007, 25, 897-898.	0.8	4
231	Prognostic Role of CA-125 Nadir in Stage IV Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1771-1772.	0.8	4
232	PG 3.01 Clinical implications of the intrinsic molecular subtypes. <i>Breast</i> , 2015, 24, S5-S6.	0.9	4
233	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	1.4	4
234	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b ComPLEEment-1 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1056-1056.	0.8	4

#	ARTICLE	IF	CITATIONS
235	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 1011-1011.	0.8	4
236	A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.. Journal of Clinical Oncology, 2020, 38, TPS1105-TPS1105.	0.8	4
237	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget, 2016, 7, 67956-67965.	0.8	4
238	Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.. Journal of Clinical Oncology, 2022, 40, 518-518.	0.8	4
239	Abstract GS1-04: Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. Cancer Research, 2021, 81, GS1-04-GS1-04.	0.4	3
240	Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial). , 2021, , .		3
241	Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. , 2017, , .		3
242	Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer. , 2018, , .		3
243	Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.. Journal of Clinical Oncology, 2011, 29, 502-502.	0.8	3
244	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. Journal of Clinical Oncology, 2018, 36, 1025-1025.	0.8	3
245	Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.. Journal of Clinical Oncology, 2018, 36, 438-438.	0.8	3
246	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Frontiers in Oncology, 2021, 11, 744112.	1.3	3
247	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Frontiers in Immunology, 2021, 12, 792609.	2.2	3
248	Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i> -mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A. Cancer Research, 2022, 82, P1-18-03-P1-18-03.	0.4	3
249	Abstract PD15-01: Impact of <i>ESK1</i> mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i> -mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial. Cancer Research, 2022, 82, PD15-01-PD15-01.	0.4	3
250	Acute severe hypothyroidism induced by sunitinib. Radiotherapy and Oncology, 2008, 89, 124-125.	0.3	2
251	Reply to Y. Yamamoto et al. Journal of Clinical Oncology, 2013, 31, 2517-2518.	0.8	2
252	Molecular Tumor Boards. Breast Care, 2018, 13, 137-139.	0.8	2

#	ARTICLE	IF	CITATIONS
253	Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. <i>Annals of Oncology</i> , 2019, 30, v81.	0.6	2
254	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 73.	2.3	2
255	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. <i>Annals of Hematology</i> , 2021, 100, 2997-3005.	0.8	2
256	S5-2: PAM50 HER2 ⁺ Enriched Subtype Enriches for Tumor Response to Neoadjuvant Anthracyclines/Taxane and Trastuzumab/Taxane Containing Regimens in HER2 ⁺ Positive Breast Cancer.. , 2011, , .		2
257	Abstract P2-09-04: Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer. , 2018, , .		2
258	Abstract P4-04-05: Primary endocrine therapy (PETx) induces PAM50 intrinsic subtype migration with prognostic implications. , 2018, , .		2
259	Gene expression-based predictors of chemotherapy response in basal-like breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10500-10500.	0.8	2
260	A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3105-TPS3105.	0.8	2
261	Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11049-11049.	0.8	2
262	Molecular Classification of Breast Cancer. , 2016, , 203-219.		2
263	Association between genotypes, clinical scores and survival outcome in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3553-3553.	0.8	2
264	Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. <i>Cancer Research</i> , 2022, 82, P4-10-04-P4-10-04.	0.4	2
265	Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3). <i>Cancer Research</i> , 2022, 82, PD13-04-PD13-04.	0.4	2
266	Abstract OT2-11-07: Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial). <i>Cancer Research</i> , 2022, 82, OT2-11-07-OT2-11-07.	0.4	2
267	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. <i>Cancer Research</i> , 2022, 82, PD2-05-PD2-05.	0.4	2
268	Abstract OT-09-08: Solti-1502 aRIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer. , 2021, , .		1
269	Abstract OT-03-07: Solti-1804 HER2-PREDICT: A biomarker research study of DS8201-A-U301 -U302 and -U303 trials. , 2021, , .		1
270	A phase 1b study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1057-1057.	0.8	1

#	ARTICLE	IF	CITATIONS
271	Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.. Journal of Clinical Oncology, 2021, 39, 1574-1574.	0.8	1
272	Abstract P2-09-11: PAM50 intrinsic subtyping as a predictor of pathological complete response to neoadjuvant trastuzumab-based chemotherapy in early HER2-positive breast cancer. , 2018, , .		1
273	PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, TPS642-TPS642.	0.8	1
274	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. Journal of Clinical Oncology, 2019, 37, 1050-1050.	0.8	1
275	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. Journal of Clinical Oncology, 2019, 37, 575-575.	0.8	1
276	Cell plasticity associated to taxane-resistance in preclinical cell models and in circulating tumor cells from metastatic castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2019, 37, 238-238.	0.8	1
277	Abstract 3328: Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. , 2011, , .		1
278	Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2018, 36, e16579-e16579.	0.8	1
279	Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05). Cancer Research, 2022, 82, P4-10-01-P4-10-01.	0.4	1
280	Abstract OT1-17-01: Solti-1716. Targeting with pembrolizumab + paclitaxel non-luminal by PAM50 hormone receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK4/6 inhibitor treatment (TATEN trial). Cancer Research, 2022, 82, OT1-17-01-OT1-17-01.	0.4	1
281	Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC). Cancer Research, 2022, 82, OT2-27-01-OT2-27-01.	0.4	1
282	Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. Cancer Research, 2022, 82, P2-14-13-P2-14-13.	0.4	1
283	Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). Cancer Research, 2022, 82, P1-07-02-P1-07-02.	0.4	1
284	Abstract OT2-19-03: Solti-1801. Analysis of the efficacy of CDK4/6 inhibitors in combination with hormonal treatment in luminal breast cancer in relation to the intrinsic subtype and markers of immunity (CDK-predict). Cancer Research, 2022, 82, OT2-19-03-OT2-19-03.	0.4	1
285	Prevalence of incidental pathogenic germline variants detected in cfDNA in patients with oncogene-driven non-small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 10569-10569.	0.8	1
286	Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy.. Journal of Clinical Oncology, 2022, 40, e12504-e12504.	0.8	1
287	160 INVITED Biopsy-driven biomarker development: pharmacodynamic studies in early clinical trials. European Journal of Cancer, Supplement, 2007, 5, 43-44.	2.2	0
288	Molecular classification of triple-negative tumors. Breast Cancer Research, 2011, 13, .	2.2	0

#	ARTICLE	IF	CITATIONS
289	Response. Journal of the National Cancer Institute, 2015, 107, djv029-djv029.	3.0	0
290	Pertuzumab Use in the Adjuvant Setting: Why Not?. Journal of Clinical Oncology, 2017, 35, 1138-1138.	0.8	0
291	What's New in Biology. Breast, 2017, 36, S29.	0.9	0
292	Implementing preoperative endocrine therapy in breast cancer. Lancet Oncology, The, 2020, 21, 1390-1392.	5.1	0
293	Abstract 1075: AXL is a potential druggable target in trastuzumab resistance in HER2+ breast cancer patients. , 2021, , .		0
294	Validation of CA-125 concentration nadir within the normal range following primary treatment as a predictor of survival for epithelial ovarian cancer (EOC). Journal of Clinical Oncology, 2007, 25, 16007-16007.	0.8	0
295	Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance.. , 2013, , .		0
296	Abstract 4452: p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer.. , 2013, , .		0
297	Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+ breast cancer as a mechanism of HER2 resistance.. Journal of Clinical Oncology, 2013, 31, 11021-11021.	0.8	0
298	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation, 2014, 124, 1418-1418.	3.9	0
299	Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2015, 33, 569-569.	0.8	0
300	High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.. Journal of Clinical Oncology, 2016, 34, e14552-e14552.	0.8	0
301	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. Journal of Clinical Oncology, 2016, 34, 3033-3033.	0.8	0
302	Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab.. Journal of Clinical Oncology, 2018, 36, e12634-e12634.	0.8	0
303	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. Journal of Clinical Oncology, 2018, 36, 3076-3076.	0.8	0
304	ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2019, 37, 207-207.	0.8	0
305	The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as a biomarker of taxane resistance in castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 235-235.	0.8	0
306	Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience.. Journal of Clinical Oncology, 2020, 38, 560-560.	0.8	0

#	ARTICLE	IF	CITATIONS
307	Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes.. Journal of Clinical Oncology, 2020, 38, 164-164.	0.8	0
308	Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC) patients.. Journal of Clinical Oncology, 2020, 38, 165-165.	0.8	0
309	806â€¦Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. , 2020, , .		0
310	Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer. Cancer Research, 2022, 82, P2-15-01-P2-15-01.	0.4	0
311	Abstract TF2-3: Molecular heterogeneity in HER2+ breast cancer - can outcomes be predicted?. Cancer Research, 2022, 82, TF2-3-TF2-3.	0.4	0
312	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. Cancer Research, 2022, 82, P4-06-08-P4-06-08.	0.4	0
313	Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303) Tj ETQq1 1 0.784314 rgBT /Ower Cancer Research, 2022, 82, PD8-03-PD8-03.	0.4	0
314	Abstract OT1-12-01: Solti-1804 HER2-PREDICT: Translational study of tumor samples from breast cancer patients treated with trastuzumab deruxtecan in the metastatic setting. Cancer Research, 2022, 82, OT1-12-01-OT1-12-01.	0.4	0
315	Circulating tumor DNA profile in pancreatic ductal adenocarcinoma (PDAC) and potential targeted therapy.. Journal of Clinical Oncology, 2022, 40, 4152-4152.	0.8	0
316	Consensus on the utility of breast cancer multigene signatures in routine clinical practice: Results of the PROCURE Project.. Journal of Clinical Oncology, 2022, 40, e13639-e13639.	0.8	0
317	<i>PBRM1</i> genomic alterations as a predictive biomarker to immune checkpoint inhibitors (ICI) and/or anti-angiogenic therapies (anti-VEGF) in metastatic renal cell carcinoma (mRCC): A systematic review and meta-analysis.. Journal of Clinical Oncology, 2022, 40, e16515-e16515.	0.8	0
318	The FLARE score, circulating neutrophils, and association with COVID-19 outcomes in patients with solid tumors.. Journal of Clinical Oncology, 2022, 40, 2551-2551.	0.8	0
319	Estrogen receptor $\hat{1}^2$ and <i>TMPRSS2-ERG</i> expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5077-5077.	0.8	0